Clinical Trial Search

Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Primary Composite Endpoint — 654; 611 participants — p=0.1969

Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants

Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001

Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries

Primary: Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors — 34.2; 17.5 percentage of participants

Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001

Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second

Primary: Primary Composite Endpoint — 844; 832 participants — p=0.945

Primary: Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV)…

Primary: Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. — 1.034; 0.913 mg per litre (mg/L) — p=0.348

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 17; 10; 11; 12 Participants

Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants

Primary: Total Knowledge Score — 2.83; 4.0 knowledge score

Primary: Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1) — 75.2; 67.7 % (n/N)

Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants

Primary: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial…

Primary: Change From Baseline Lipid Pool to Follow up as Assessed by NIRS/IVUS With Treatment of Ticagrelor

Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup

Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2

Primary: Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images — 56 Participants

Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05

Primary: Among Patients With an Appropriate ICD Therapy (Shock or ATP) for Ventricular Tachycardia or Fibrillation, the Number of Patients Who Have Characterized ST Segment…

Primary: Number of Treatment-related Adverse Events — 6 Adverse events